ePRO Monitoring for Chronic Disease Care Transitions
Trial Summary
What is the purpose of this trial?
This study aims to predict and minimize post-discharge adverse events (AEs) during care transitions through early identification and escalation of patient-reported symptoms to inpatient and ambulatory clinicians by way of predictive algorithms and clinically integrated digital health apps. We will (1) develop and prospectively validate a predictive model of post-discharge AEs for patients with multiple chronic conditions (MCC); (2) combine, adapt, extend, and iteratively refine our EHR-integrated digital health infrastructure in a series of design sessions with patient and clinician participants; (3) conduct a RCT to evaluate the impact of ePRO monitoring on post-discharge AEs for MCC patients discharged from the general medicine service across Brigham Health; and (4) use mixed methods to evaluate barriers and facilitators of implementation and use as we develop a plan for sustainability, scale, and dissemination.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the ePRO Application treatment for chronic disease care transitions?
Research shows that using telecommunications and surveillance technologies in care transitions can help monitor patients' conditions after hospital discharge, reducing the risk of negative health outcomes. This suggests that the ePRO Application, which likely uses similar technology, could be effective in improving care transitions for patients with chronic diseases.12345
Is the ePRO Monitoring for Chronic Disease Care Transitions generally safe for humans?
The research articles focus on medication safety during care transitions and suggest that electronic tools, like medication reconciliation applications, can help reduce risks associated with medication discrepancies. While these studies do not directly address the safety of ePRO Monitoring, they indicate that electronic interventions in care transitions are generally aimed at improving safety.678910
How is the ePRO Application treatment different from other treatments for chronic disease care transitions?
Research Team
Anuj K Dalal, MD
Principal Investigator
Brigham and Women's Hospital
Eligibility Criteria
This trial is for adults with two or more chronic conditions like heart disease, diabetes, COPD, etc., who are hospitalized and will be discharged to home or a facility. They must speak English or have an English-speaking healthcare proxy.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Pre-implementation
Development and validation of a predictive model of post-discharge AEs for MCC patients using PRO questionnaires and EHR-derived variables
Main Trial (RCT) Period
Randomized controlled trial comparing real-time symptom monitoring intervention to usual care for patients with MCCs transitioning out of the hospital
Follow-up
Participants are monitored for safety and effectiveness after discharge, focusing on adverse events and healthcare utilization
Treatment Details
Interventions
- ePRO Application (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Dr. William Curry
Brigham and Women's Hospital
Chief Medical Officer
MD from Columbia University College of Physicians and Surgeons
Dr. Scott Schissel
Brigham and Women's Hospital
Chief Executive Officer since 2021
MD from Columbia University College of Physicians and Surgeons
RAND
Collaborator
Rand Sutherland
RAND
Chief Medical Officer since 2024
MD from University of Chicago
Jason Matheny
RAND
Chief Executive Officer since 2022
PhD in Public Policy, Harvard University